HHorinouchi· @HHorinouchi · X·· 2 天前评分60
正文 · 原文
🆙#ESMO26 Proffered Paper: #LCSM Non-Mets 🔥DeLLphi-304: Tarlatamab in Previously Treated SCLC: Extended Follow-Up of Overall Survival From the Phase 3 Trial 🎙️ @charlesrudin 🔢3808O 🎯Durable OS Benefit at 23-Mo Median Follow-Up 🎯mOS 13.6 vs 8.4mo (HR 0.62); 18-Mo OS 42% vs 24% 🎯Grade≥3 TRAEs 28% vs 63% ☑️NCT05740566 🔗 https://t.co/grEfaUbJVf @OncoAlert @Larvol @myESMO @IASLC
热度 5 · 4 赞 · 0 回复 · 1 转发
会议摘要
NCT05740566NCT05740566按 - **标题 / Title：** Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer 对上
- **标题 / Title：** Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer读摘要原文 →来源：HHorinouchi · x.com